Syneos Health Inc

Syneos Health — INC Research Holdings — Merger or Acquisition (May 2017)

46 slides from Syneos Health's merger presentation, May 11, 2017

  1. Slide 1: INC Research + inVentiv Health Merger

    INC Research + inVentiv Health Merger Creating a Leading Global Biopharmaceutical Solutions Organization May 10, 2017

  2. Slide 2: Important Information: Forward-Looking Statements

    Important Information Forward-Looking Statements This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such fo

  3. Slide 3: Important Information (Cont'd): Non-GAAP Financial Measures

    Important Information (Cont’d) Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with GAAP, this presentation contains certain non-GAAP financial measures, including Adjusted Income from Operations, Adjusted Operating Margin, Adjusted Net Income (including Adju

  4. Slide 4: INC Research + inVentiv Health: Purpose built for market realities

    INC Research + inVentiv Health Purpose built to address market realities where clinical and commercial must work together – sharing expertise, data and insights – to improve customer performance Infusing clinical insights into commercialization, and commercial expertise into clinical trials, to spee

  5. Slide 5: Transformational Strategic Combination

    Transformational Strategic Combination Industry Leader # 7 CRO # 6 CRO / #1 CCO Top 3 CRO / #1 CCO Strength in SMID Biopharma; limited penetration in Top 20 Biopharma Strength with Top 20 Biopharma Diversified and highly complementary customer base Therapeutic focus in oncology, CNS and Infectious D

  6. Slide 6: Creates the #2 Global Biopharmaceutical Solutions Company

    Creates the #2 Global Biopharmaceutical Solutions Company Capability A leading global Clinical Research Organization (“CRO”) A leading global CRO and Contract Commercial Organization (“CCO”) Capability Capability ~$3.2 billion 2016 Combined Net Revenue $600+ million 2016 Combined Adjusted EBITDA (be

  7. Slide 7: Significant Value Creation Opportunities

    Significant Value Creation Opportunities Mid-to-high single digit accretion in 2018 20% plus accretion in 2019 and beyond Numerous opportunities to further enhance revenue growth and margin expansion not reflected above Accelerating inVentiv Health margin expansion story Identified and achievable an

  8. Slide 8: Key Transaction Highlights

    Key Transaction Highlights Consideration Ownership Timing Management Headquarters Board of Directors INC Research to issue common stock to inVentiv Health in an all-stock transaction Values inVentiv Health at an enterprise value of ~$4.6bn and combined company at an enterprise value of ~$7.4bn based

  9. Slide 9: Global Biopharmaceutical Solutions Leader in Size and Scale

    Employees(2) 50,000 22,000+ 10,000 15,000(3) 18,500 15,200 18,600 9,100 9,200 12,500 13,000 7,300 6,900 8,000 2,500 (Covance) Note:Trademarks, service marks or trade names are the property of their respective owners. (1)Pro forma for estimated 2016 Capsugel net revenue. Foreign exchange conversion a

  10. Slide 10: A Leader in End-to-End Drug Development Solutions

    A Leader in End-to-End Drug Development Solutions Real World Evidence Data Analytics Selling Solutions Comm-unications Consulting Central Lab FSP Full Service Phases II-IV Phase I Medication Adherence Note:Trademarks, service marks or trade names are the property of their respective owners. Shading

  11. Slide 11: A Strong, Well Diversified Business

    A Strong, Well Diversified Business Ability to Serve Customers of All Sizes Comprehensive End-to-End Solutions Diversified Customer Base Solutions Mix CRO CCO Biopharma Customer Concentration (Total Company) Biopharma Customer Type (Total Company) Top 5 Other Top 6-10 Top 20 SMID Top 21-50 Note:Abov

  12. Slide 12: Clinical and Commercial Insights Inform Each Other

    Consulting Clinical Visibility and Therapeutic Experience Inform Commercialization Efforts Commercial Pricing & Marketing Insights and Enterprise Data Inform Clinical Design & Execution Selling Solutions Consulting Early Stage Full Service Strategic Resourcing CCO CRO Communications Medication Adher

  13. Slide 13: Clinical Research Organization Segment

    Clinical Research Organization Segment

  14. Slide 14: Critical Success Factors in Global Clinical Development Market

    Critical Success Factors in Today’s Global Clinical Development Market Critical Scale Strong Geographic Presence Therapeutic Depth and Expertise Delivery Model Flexibility Ability to Deliver Solutions for Customers of All Sizes Understanding Market Challenges Building a better CRO to service custome

  15. Slide 15: Creates a Global Leader in Clinical Outsourcing

    Creates a Global Leader in Clinical Outsourcing Critical Scale (Covance) Clinical Development Net Revenue(1) CRO Employees (~15,400) Support customers in 110+ countries Employees in 60+ countries 2,500+ employees in APAC ~400 in Japan (top 3 global CRO in Japan) ~250 in China ~1,200 in India Strong

  16. Slide 16: Therapeutic Area Depth and Breadth of Delivery Models

    Therapeutic Area Depth and Breadth of Delivery Models Ability to deliver solutions for all customer needs Therapeutically-aligned delivery model provides industry-leading full service offering Increasing customer desire for hybrid models Leading FSP offering with ~$500mm of annual net revenue, of wh

  17. Slide 17: Flexibility to Serve Customers of All Sizes

    Flexibility to Serve Customers of All Sizes Combination of inVentiv Health’s strength with top 20 complements INC Research strength with SMID Strong stable revenue base from top 50 – ~$1.4bn combined net revenue A leader in serving SMID biopharma with ~$700mm net revenue, a segment INC Research has

  18. Slide 18: Contract Commercial Organization Segment

    Contract Commercial Organization Segment

  19. Slide 19: Commercial Market Offers Attractive Growth Profile

    Growth in the CRO market has historically been in the high single digits, with the CCO market projected to follow a similarly strong growth path Biopharma sales and marketing budgets are significant – at least 10% greater than R&D budgets at large biopharma Shift toward specialty and more complex th

  20. Slide 20: Biopharmaceutical Operating Challenges Demand New Commercial Solutions

    Biopharmaceutical Operating Challenges Demand New Commercial Solutions Margin deterioration Fewer blockbusters with shift to specialty Global shift of care from volume to value Reimbursement and access hurdles R&D productivity Growing political pressures Reduce SG&A Optimize deployment of marketing

  21. Slide 21: Broadest Provider of Commercialization Solutions

    Broadest Provider of Commercialization Solutions Selling Solutions Communications Consulting Medication Adherence CCO Employees: ~6,400 Net Revenue: $1,186mm Adjusted EBITDA margin of ~18% #1 organization in US Largest independent global healthcare agency Pharmacy network covering ~194 million patie

  22. Slide 22: Leading Global Provider Focused on High Value Commercial Solutions

    Leading Global Provider Focused on High Value Commercial Solutions Selling Solutions P P P Communications P – P Consulting P P P Medication Adherence P – Limited Data + Insight P P P 2016 net revenue(1) $1,186 $796 $528 2016 net revenue growth(1) 12% (6%) 5% 2016 Adjusted EBITDA margin(1)(2) ~18% 9%

  23. Slide 23: Expansive Data Assets Can Drive Insights and Improve Execution

    Expansive Data Assets Can Drive Insights and Improve Execution Physician targeting and segmentation Site selection and patient recruitment Observational studies and Real World Evidence Multi-channel promotion opportunities Medication adherence programs Protocol design and feasibility Trial protocol

  24. Slide 24: Financial Highlights

    Financial Highlights

  25. Slide 25: Significantly Accelerates Growth

    ’14-’17 CAGR: 9% ’14-’17 CAGR: 48% ’14-’17 CAGR: 21% Significantly Accelerates Growth Revenue Adjusted EBITDA Adjusted EPS INC Research Standalone INC Research + inVentiv Health 2017 – 2020 CAGR 2017 – 2020 CAGR 2017 – 2020 CAGR Significantly increases addressable market Highly diversified revenue s

  26. Slide 26: Identifiable and Achievable Cost Synergies and Additional Upsides

    Identifiable and Achievable Cost Synergies and Meaningful Additional Upsides Tax Opportunities Cost Synergies Additional Margin Enhancement Opportunities Improve effective tax rate from combined of 35% to low 30’s inVentiv Health net operating losses of ~$850mm Corporate and administrative spending

  27. Slide 27: Meaningful Revenue Synergies From Cross-Selling

    Meaningful Revenue Synergies From Cross-Selling Cross-Sell Commercial Offering to Clinical Customer Base Market Combined Clinical Scale and Service Offering Utilize Commercial Insights, Data and Relationships to Increase Clinical Win-Rate INC Research’s SMID customer base represents customer set cur

  28. Slide 28: Value Creation Through Successful Integrations

    Value Creation Through Successful Integrations 7 acquisitions since 2007 25 acquisitions since 2007 MDS Global Clinical Development Kendle International 2011 2009 $41mm $56mm $9mm $12mm PharmaNet / i3 2011 $28mm $35mm 2012-2016 Value Creation 31% +910bps 20% +740bps Year Forecast Cost Synergies Cost

  29. Slide 29: Strong Pro Forma Credit Profile

    Strong Pro Forma Credit Profile Plan to opportunistically refinance capital structure, affording favorable terms, liquidity and flexibility Long-term focus on deleveraging and optimizing weighted average cost of debt, including reducing inVentiv Health Unsecured Notes 4.0x pro forma net leverage at

  30. Slide 30: INC Research Q1 2017 Highlights

    INC Research Q1 2017 Highlights Key Operating Metrics – Adjusted Basis Record quarter of net awards of ~$360mm, creating book-to-bill of 1.4x and returning INC Research to strong backlog growth of 12% Awards were broad based, including $86mm Safety FSP award and $55M from 2 new preferred provider re

  31. Slide 31: Creating a Leading Global Biopharmaceutical Solutions Organization

    Creating a Leading Global Biopharmaceutical Solutions Organization Top 3 CRO / #1 CCO Diversified and highly complementary customer base Deep therapeutic expertise, particularly complex diseases Flexibility and depth to serve customers of all sizes and needs Global leader including APAC; Top 3 globa

  32. Slide 32: Appendix

    Appendix

  33. Slide 33: Commercial Business is Well-Positioned for Growth

    Commercial Business is Well-Positioned for Growth New drug approvals have been on a steady increase over the past decade however timing of approvals can be lumpy 2016 decline (~50%) only 3rd down year since 2007 and well in excess of historical average decline of (26%) Approximately 70 compounds sch

  34. Slide 34: INC Research Q1 2017 Income Statement

    INC Research Q1 2017 Income Statement Income Statement – Adjusted Basis Note:Due to rounding of specific line items, line item figures might not sum to subtotals. For a complete reconciliation of GAAP to Non-GAAP measures for the current and historical periods presented, please refer to slides 36-38

  35. Slide 35: INC Research Backlog Should Support Long-Term Growth

    INC Research Backlog Should Support Long-Term Growth Note:Due to rounding of specific line items, line item figures might not sum to subtotals. (1)2017 revenue estimate represents the mid-point of the updated guidance range on slide 35 of this presentation. (2)CNS was updated during Q2 2016 to inclu

  36. Slide 36: INC Research Full Year 2017 Guidance

    INC Research Full Year 2017 Guidance Note:Financial guidance takes into account a number of factors, including INC Research sales pipeline, existing backlog and expectations for net awards, current foreign currency exchange rates, current interest rates, and expected tax rate, and does not take into

  37. Slide 37: INC Research Q2 2017 Guidance

    INC Research Q2 2017 Guidance 36 Note:Financial guidance takes into account a number of factors, including INC Research sales pipeline, existing backlog and expectations for net awards, current foreign currency exchange rates, current interest rates, and expected tax rate, and does not take into acc

  38. Slide 38: INC Research FY 2017 Guidance Reconciliation

    INC Research FY 2017 Guidance Reconciliation 37 Adjustments are estimates with an estimated range of +/- 5% and are presented gross without the benefit of income tax reduction Income tax effect of share-based compensation is calculated using the statutory rates applicable to the tax jurisdictions of

  39. Slide 39: INC Research Q2 2017 Guidance Reconciliation

    INC Research Q2 2017 Guidance Reconciliation 38 Adjustments are estimates with an estimated range of +/- 5% and are presented gross without the benefit of income tax reduction Income tax expense is calculated and the adjustments are tax-affected at an approximate rate of 32%, which is the midpoint o

  40. Slide 40: INC Research Non-GAAP Financials

    INC Research Non-GAAP Financials $mm Fiscal Year Ending December 31, 2014 2015 2016 Q1 ‘16 Q1 ‘17 LTM Net Income (loss) ($23.5) $117.0 $112.6 $17.4 $21.2 $116.4 Interest expense, net 52.8 15.4 11.8 3.0 3.0 11.8 Income tax provision (benefit) (4.7) 13.9 21.5 7.0 7.1 21.6 Depreciation and Amortization

  41. Slide 41: INC Research Non-GAAP Financials (Cont'd)

    INC Research Non-GAAP Financials (Cont’d) $mm Fiscal Year Ending December 31, 2014 2015 2016 Q1 ‘16 Q1 ‘17 Net Income (loss) ($23.5) $117.0 112.6 $17.4 $21.2 Amortization 32.9 37.9 37.9 9.5 9.5 Restructuring and other costs (a) 6.2 1.8 13.6 6.0 1.9 Stock based compensation (b) 3.4 5.1 14.0 2.8 5.8 T

  42. Slide 42: INC Research Non-GAAP Financials (Cont'd)

    INC Research Non-GAAP Financials (Cont’d) (a)Restructuring, CEO transition, and other costs consist primarily of: (i) severance costs associated with a reduction of workforce in line with the Company's expectations of future business operations, (ii) transition costs associated with the change in th

  43. Slide 43: inVentiv Health Financial Overview

    inVentiv Health Financial Overview ($ in millions) CAGR: 10% ($ in millions) CAGR: 29% % margin CAGR: 6% CAGR: 26% % margin CAGR: 15% CAGR: 22% % margin Mid-single digit Adjusted EBITDA growth Double-digit growth in clinical Commercial/corporate down mid-single digits due to double digit revenue dec

  44. Slide 44: inVentiv Health Estimated and Preliminary Q1 2017 Highlights

    inVentiv Health Estimated and Preliminary Q1 2017 Highlights $mm (except ratios) Three Months Ended March 31, 2016 2017 % Change Total Company: Net Service Revenue 541.3 533.8(1) (1.4%) Adjusted EBITDA 85.0 96.7 13.7% Adjusted EBITDA margin 15.7% 18.1% ~240bps Selected Clinical Metrics: Net New Busi

  45. Slide 45: inVentiv Health Non-GAAP Financials

    inVentiv Health Non-GAAP Financials $mm Fiscal Year Ending December 31, 2013 2014 2015 2016 Q1 ‘16 Q1 ‘17 LTM Net Income (loss) ($236.4) ($188.8) ($150.6) ($183.6) ($18.6) ($40.7) ($205.7) Interest expense, net 209.2 217.0 228.2 231.7 55.9 37.7 213.6 Income tax provision (benefit) 3.0 2.5 5.6 (8.2)

  46. Slide 46: inVentiv Health Non-GAAP Financials (Cont'd)

    inVentiv Health Non-GAAP Financials (Cont’d) (a)Represents non-cash losses associated with the impairment of goodwill, intangible assets and other long-lived assets. (b)Represents stock-based compensation charges in the income statement. (c)Represents non-cash adjustments resulting from the revaluat

INC Research Holdings — Merger or Acquisition (May 2017) on 6ix